GlassScriptPhysician profile
Divya Mallam
NPI 1437437613
$5,943.95
in general payments reported to CMS, 2019-2025
25 companies · $3,615 in 2025
The $3,615 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $98.80 · 2021: $209 · 2022: $143 · 2023: $483 · 2024: $1,395 · 2025: $3,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,493.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,767.10 | 2022-2025 | Xifaxan, Relistor, Trulance |
| Abbvie INC. | $795.74 | 2020-2025 | |
| Janssen Biotech, INC. | $631.93 | 2020-2025 | Tremfya |
| Celltrion USA INC. | $489.83 | 2025 | Vegzelma |
| Pfizer INC. | $420.21 | 2024-2025 | |
| Ardelyx, INC. | $270.39 | 2025 | Ibsrela |
| Qol Medical, LLC | $188.20 | 2025 | Sucraid |
| Genzyme Corporation | $166.29 | 2023-2024 | |
| Celgene Corporation | $166.20 | 2023-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $139.99 | 2024 | Zeposia |
| Gilead Sciences, INC. | $132.59 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.49 | 2023-2025 | Entyvio, Gattex |
| Phathom Pharmaceuticals, INC. | $97.00 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $78.70 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $72.44 | 2023-2024 | Sutab, Suflave |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $68.80 | 2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $63.46 | 2021-2023 | Ocaliva |
| Redhill Biopharma INC. | $55.84 | 2020-2025 | Talicia |
| Ironwood Pharmaceuticals, INC | $44.37 | 2024 | |
| Abbott Laboratories | $39.90 | 2022 | |
| Fresenius Kabi USA, LLC | $34.70 | 2023 | |
| Madrigal Pharmaceuticals | $29.76 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $27.73 | 2025 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $23.09 | 2021 | |
| Evoke Pharma, INC. | $16.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divya Mallam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.